Fritzsche F R, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G
Institute of Pathology, Charité--Universitätsmedizin Berlin, Berlin, Germany.
Histol Histopathol. 2007 Jul;22(7):703-8. doi: 10.14670/HH-22.703.
We aimed to evaluate immunohistochemically the expression of the human Anterior Gradient-2 (AGR2), a gene which has recently been proposed as an oncogene for lung carcinoma development, in non small cell lung cancer and to correlate the findings to clinico-pathological data including patient survival. 95 cases of NSCLC were immunostained using a polyclonal AGR2 antibody and statistical analyses were applied to test for prognostic and diagnostic associations. AGR2 was expressed in 66.3% of cases, preferentially adenocarcinomas. There were no relevant associations with clinico-pathological parameters. A prognostic value of AGR2 could not be demonstrated neither in multivariate nor in univariate analyses. Interestingly, this is the first study to demonstrate AGR2 expression in squamous cell carcinomas. Although a prognostic value of AGR2 seems unlikely further studies are warranted to investigate the biological role of AGR2 in NSCLC and its differential expression according to histology.
我们旨在通过免疫组织化学方法评估人类前梯度蛋白2（AGR2）的表达情况。AGR2基因最近被认为是肺癌发生发展中的一种癌基因。我们对非小细胞肺癌进行了研究，并将结果与包括患者生存率在内的临床病理数据相关联。使用多克隆AGR2抗体对95例非小细胞肺癌病例进行免疫染色，并应用统计分析来检验其预后和诊断相关性。AGR2在66.3%的病例中表达，腺癌中表达更为常见。AGR2与临床病理参数无显著相关性。在多变量和单变量分析中均未证明AGR2具有预后价值。有趣的是，这是第一项证明AGR2在鳞状细胞癌中表达的研究。尽管AGR2似乎不太可能具有预后价值，但仍需要进一步研究来探讨AGR2在非小细胞肺癌中的生物学作用及其根据组织学的差异表达。
